FXYD5 and thyroid cancer: Our cell proliferation assays demonstrate that in sub-nanomolar concentrations, EDC1 shows selective and dose dependent inhibition of thyroid cancer cell growth when they express moderate to high levels of dysadherin, leaving cells that do not express dysadherin unharmed.